Bristol Myers Squibb Stock Net Income
| BMYMP Stock | USD 1,003 2.93 0.29% |
As of the 15th of February 2026, Bristol-Myers Squibb shows the Mean Deviation of 1.09, risk adjusted performance of 0.124, and Downside Deviation of 3.88. Bristol Myers Squibb technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Bristol-Myers Squibb's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bristol-Myers Squibb's valuation are summarized below:Bristol Myers Squibb does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Bristol-Myers |
Bristol-Myers Squibb 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bristol-Myers Squibb's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bristol-Myers Squibb.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Bristol-Myers Squibb on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Bristol Myers Squibb or generate 0.0% return on investment in Bristol-Myers Squibb over 90 days. Bristol-Myers Squibb is related to or competes with Roche Holding, Roche Holding, Roche Holding, AstraZeneca PLC, Novartis, Sanofi, and GSK Plc. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical pro... More
Bristol-Myers Squibb Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bristol-Myers Squibb's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bristol Myers Squibb upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.88 | |||
| Information Ratio | 0.1131 | |||
| Maximum Drawdown | 13.48 | |||
| Value At Risk | (1.27) | |||
| Potential Upside | 4.04 |
Bristol-Myers Squibb Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bristol-Myers Squibb's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bristol-Myers Squibb's standard deviation. In reality, there are many statistical measures that can use Bristol-Myers Squibb historical prices to predict the future Bristol-Myers Squibb's volatility.| Risk Adjusted Performance | 0.124 | |||
| Jensen Alpha | 0.2954 | |||
| Total Risk Alpha | 0.1424 | |||
| Sortino Ratio | 0.0619 | |||
| Treynor Ratio | 3.68 |
Bristol-Myers Squibb February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.124 | |||
| Market Risk Adjusted Performance | 3.69 | |||
| Mean Deviation | 1.09 | |||
| Semi Deviation | 1.4 | |||
| Downside Deviation | 3.88 | |||
| Coefficient Of Variation | 685.08 | |||
| Standard Deviation | 2.13 | |||
| Variance | 4.52 | |||
| Information Ratio | 0.1131 | |||
| Jensen Alpha | 0.2954 | |||
| Total Risk Alpha | 0.1424 | |||
| Sortino Ratio | 0.0619 | |||
| Treynor Ratio | 3.68 | |||
| Maximum Drawdown | 13.48 | |||
| Value At Risk | (1.27) | |||
| Potential Upside | 4.04 | |||
| Downside Variance | 15.08 | |||
| Semi Variance | 1.96 | |||
| Expected Short fall | (1.69) | |||
| Skewness | (0.33) | |||
| Kurtosis | 9.25 |
Bristol Myers Squibb Backtested Returns
Bristol-Myers Squibb appears to be very steady, given 3 months investment horizon. Bristol Myers Squibb secures Sharpe Ratio (or Efficiency) of 0.18, which signifies that the company had a 0.18 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Bristol Myers Squibb, which you can use to evaluate the volatility of the firm. Please makes use of Bristol-Myers Squibb's Mean Deviation of 1.09, risk adjusted performance of 0.124, and Downside Deviation of 3.88 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Bristol-Myers Squibb holds a performance score of 14. The firm shows a Beta (market volatility) of 0.0817, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Bristol-Myers Squibb's returns are expected to increase less than the market. However, during the bear market, the loss of holding Bristol-Myers Squibb is expected to be smaller as well. Please check Bristol-Myers Squibb's potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether Bristol-Myers Squibb's price patterns will revert.
Auto-correlation | 0.17 |
Very weak predictability
Bristol Myers Squibb has very weak predictability. Overlapping area represents the amount of predictability between Bristol-Myers Squibb time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bristol Myers Squibb price movement. The serial correlation of 0.17 indicates that over 17.0% of current Bristol-Myers Squibb price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | 0.48 | |
| Residual Average | 0.0 | |
| Price Variance | 2262.36 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Bristol Myers Squibb reported net income of 7.01 B. This is much higher than that of the Healthcare sector and 72.06% higher than that of the Drug Manufacturers - Major industry. The net income for all United States stocks is significantly lower than that of the firm.
Bristol-Myers Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol-Myers Squibb's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bristol-Myers Squibb could also be used in its relative valuation, which is a method of valuing Bristol-Myers Squibb by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in net income category among its peers.
Bristol-Myers Fundamentals
| Revenue | 46.38 B | |||
| EBITDA | 20.1 B | |||
| Net Income | 7.01 B | |||
| Cash And Equivalents | 6.07 B | |||
| Cash Per Share | 3.72 X | |||
| Total Debt | 39.6 B | |||
| Debt To Equity | 59.40 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 7.55 X | |||
| Cash Flow From Operations | 16.21 B | |||
| Number Of Employees | 23.7 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 2.11 T | |||
| Total Asset | 109.31 B | |||
| Annual Yield | 0 % | |||
| Net Asset | 109.31 B | |||
| Last Dividend Paid | 1.59 |
About Bristol-Myers Squibb Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol-Myers Squibb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bristol-Myers Squibb
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.Moving against Bristol-Myers Pink Sheet
| 0.6 | PBCRF | PT Bank Central | PairCorr |
| 0.46 | PTAIF | PT Astra International | PairCorr |
| 0.46 | KUKE | Kuke Music Holding | PairCorr |
The ability to find closely correlated positions to Bristol-Myers Squibb could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol-Myers Squibb when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol-Myers Squibb - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol-Myers Squibb is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol-Myers Squibb moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol-Myers Squibb can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Bristol-Myers Pink Sheet Analysis
When running Bristol-Myers Squibb's price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.